Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Express Co (AXP) vs Novavax Inc (NVAX) Price & Performance

American Express CoTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

American Express Co vs Novavax Inc — how do they compare? American Express Co trades at $341.2 (market cap $230.15B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: American Express Co is far larger — about 175.7× Novavax Inc's market cap, and American Express Co pays a 1.11% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

AXPNVAX
Market Cap
$230.15B$1.31B
Sector
FinancialsHealth
52-Week High
$384.82$11.19
52-Week Low
$292.27$6.22
Dividend Yield
1.11%
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Express Co

AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.

Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Express Co

American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.

Read more on AXP

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX